New guidelines have been developed for the treatment of schizophrenia through a collaborative effort of international experts ...

A study published in Nature Chemistry by researchers from the University of Pittsburgh and Yale University shows how common ...

Successful treatment for schizophrenia involves a mix of medication and therapy. People who do both are less likely to have a relapse or wind up in the hospital. Studies show this treatment ...

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S.

Schizophrenia is a condition requiring long-term medication management. A person living with the condition will benefit from treatments that help them manage their symptoms and prevent chances of ...

Abilify Maintena and Abilify Asimtufii are approved to treat schizophrenia and bipolar I disorder‡ in adults. Abilify belongs to a drug class called antipsychotics. Abilify oral tablet is ...

A 33-year-old woman hears brutal and frightening voices daily but continues her college studies. A middle-aged man, who served in the Navy and has since struggled with substance ...

After decades of stagnation in the drug treatment of schizophrenia, a handful of new therapies have raised hopes of improvement – but one of them has just failed a pair of phase 3 trials.

A new study, published today in Nature Chemistry by researchers from the University of Pittsburgh and Yale University, shows how common gut bacteria can metabolize certain oral medications that target ...

Scientists at Johns Hopkins Medicine have discovered that an experimental drug originally developed for other health problems ...

was submitted to the U.S. Food and Drug Administration (FDA) requesting marketing approval of Bysanti (milsaperidone) for the treatments of acute bipolar I disorder and schizophrenia. The NDA is ...